Related Experiment Video

Updated: Aug 13, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells

Junichi Kurebayashi1, Sumiko Okubo, Yutaka Yamamoto

  • 1Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, 701-0192, Okayama, Japan. kure@med.kawasaki-m.ac.jp

Cancer Chemotherapy and Pharmacology
|January 26, 2006
PubMed
Abstract

Insights

Molecular targeting agents gefitinib and imatinib show antitumor activity against anaplastic thyroid cancer (ATC) cells. Combined treatment demonstrated enhanced apoptosis and inhibited tumor growth, suggesting greater efficacy than monotherapy for this aggressive cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anaplastic thyroid cancer (ATC) is a highly aggressive malignancy with a poor prognosis, often with survival less than one year despite multidisciplinary treatments.
  • Investigating novel therapeutic strategies, including molecular targeting agents, is crucial for improving outcomes in ATC patients.

Purpose of the Study:

  • To evaluate the antitumor activity of two tyrosine kinase inhibitors, gefitinib and imatinib, in anaplastic thyroid cancer cell lines.
  • To determine the efficacy of combined gefitinib and imatinib treatment against ATC cells and xenografts.

Main Methods:

  • Tested gefitinib and imatinib on poorly differentiated thyroid cancer (KTC-1) and ATC cell lines (KTC-2, KTC-3).
  • Assessed expression of target molecules (HER1, HER2, c-ABL, PDGF receptors) in cell lines.
  • Evaluated antitumor activity, apoptosis induction, and effects on antiapoptotic proteins (Bcl-2, Bcl-xL).
  • Investigated combined treatment efficacy in KTC-3 xenografts in nude mice.

Main Results:

  • All tested cell lines expressed target molecules for both gefitinib and imatinib.
  • Both gefitinib and imatinib exhibited modest antitumor activity individually.
  • Combined treatment with gefitinib and imatinib showed an additive antitumor effect, enhanced apoptosis, and downregulated Bcl-2 and Bcl-xL.
  • Combined therapy significantly inhibited KTC-3 xenograft growth in vivo.

Conclusions:

  • Gefitinib and imatinib possess antitumor activity against anaplastic thyroid cancer cells.
  • Combination therapy with gefitinib and imatinib demonstrates superior efficacy compared to monotherapy.
  • These findings support the potential of combined tyrosine kinase inhibition as a therapeutic strategy for anaplastic thyroid cancer.

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...